Hematological Cancer (Blood Cancer) Therapeutics- Market Insights, Competitive Landscape and, Market Forecast - 2027

Hematological Cancer (Blood Cancer) Therapeutics- Market Insights, Competitive Landscape and, Market Forecast - 2027

Hematological Cancer (Blood Cancer) Therapeutics By Indication (Leukemia, Lymphoma, And Myeloma), By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, And Other Therapies), By End-User (Hospital Pharmacies, Retail Pharmacy, And Others) and by geography is expected to grow at a steady CAGR forecast till 2027 owing to the increasing prevalence of blood cancer and increasing prevalence of lifestyle disorders worldwide

The global hematological cancer or blood cancer therapeutic market was valued at USD 56.59 billion in 2021, growing at a CAGR of 10.14% during the forecast period from 2022 to 2027 to reach USD 100.80 billion by 2027. The hematological cancer (blood cancer) therapeutics market is witnessing positive growth owing to various factors such as rising cases of blood cancer due to gene or DNA mutation, exposure to carcinogenic substances, smoking, among others. Additionally, increasing prevalence of lifestyle disorders such as diabetes, hypertension, obesity, hyperlipidemia, and others due to sedentary lifestyle & unhealthy eating will also contribute in the growth of hematological cancer therapeutics market. Further, increasing research and development activities in arena of leukemia and its treatment across the globe will also aid in the growth of the hematological cancer (blood cancer) therapeutics market. Therefore, the market for hematological cancer (blood cancer) therapeutics is estimated to grow at a significant CAGR during the forecast period from 2022 to 2027.

Hematological Cancer (Blood Cancer) Therapeutics Dynamics:

One of the main driver for the hematological cancer (blood cancer) therapeutics market is the increasing figures of blood cancer across the globe due to the rising sedentary and unhealthy lifestyle, gene mutations, increasing exposure to smoking, alcohol, carcinogenic substances, among others.

For instance, as per the data given by Cancer Fact Sheet 2022, it is estimated that in the year 2022, an estimated 60,650 new cases of leukaemia will be diagnosed in the United States and 24,000 people will die from the disease. Moreover, as per the US department of Health and Human Services, 2022, it was estimated that in the year 2019, 72,714 people living with leukaemia in the United States.

Also, as per the data published by European Commission, the incidence of leukaemia is also increasing in the Europe. The source estimated that in the year 2020, there were total 11720 people suffering from blood cancer. As per the same source, in the Germany, nearly 13796 people suffered from blood cancers in the same year.

Additionally, the Blood Cancer UK, 2022, stated that there were about 250,000 people living with blood cancer in the United Kingdom, in the year 2021. The source also stated that one in every 16 men and one in every 22 women will develop it at some point in their lives.

Thus, the increasing prevalence of blood cancer in the different regions in the world will increase the demand of its therapy, thereby spurring the overall market growth of haematological cancer therapeutics.

Further, smoking, radiation exposure, and exposure to certain chemicals have all been linked to the increased risk of some types of blood cancers. Epstein-Barr virus, HIV and human T-cell lymphoma/leukaemia virus infections are also risk factors for developing lymphomas and leukaemia. Thus, increased exposure to any of the above factor will increase the number of cases of blood cancer, ultimately increasing the demand of haematological cancer therapeutics in the upcoming years. According to the World Health Organization (WHO) 2022, in 2020, 22.3% of the global population used tobacco, 36.7% of all men and 7.8% of the world’s women. Thus, the increased consumption of tobacco will further increase the prevalence of blood cancer, ultimately increasing the demand of blood cancer therapeutics in the forecast period.

Therefore, the factors stated above collectively will drive the overall hematological cancer or blood cancer therapeutics during the forecast period from 2022-2027.

However, high cost of therapy, serious adverse drug reactions of therapy, and others, can hinder the global hematological cancer (blood cancer) therapeutics market growth.

The COVID-19 pandemic has slightly impacted the market for hematological cancer (blood cancer) therapy. The outbreak of the pandemic led to the cancellation of outpatient visits and the suspension of non-emergency hospitals and procedures for chronic disorders such as cancers, diabetes, cardiovascular disorders, others. This resulted in the reduced number of patients for the routine treatments of the above mentioned disorders. However, vaccine development of COVID-19 has produced the process of economic recovery with the easing of lockdown restrictions and the return of normalcy in the economic landscape which has initiated the process of resumption of regular healthcare services such as outpatient’s visits, thereby bringing the demand for products on track in the hematological cancer (blood cancer) therapy market.

Hematological Cancer (Blood Cancer) Therapeutics Segment Analysis:

Hematological Cancer (Blood Cancer) Therapeutics By Indication (Leukemia, Lymphoma, and Myeloma), Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, and Other Therapies), End-User (Hospital Pharmacies, Retail Pharmacy, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the therapy segment of the hematological cancer (blood cancer) therapeutics, the chemotherapy market is expected to have a significant revenue share in the year 2021. This was primarily owing to the increasing advantages offered by the segment.

Chemotherapy is one of the major therapy for the treatment of various cancers including leukemia. Chemotherapy may shrink the cancer cells present in the blood or slow down its growth, which may help the patients live longer and help with the symptoms. For a small number of people with borderline blood cancer, chemotherapy may shrink the cancer enough to make surgery to remove the cancer possible. Thus, making it an apt treatment for patients with borderline blood cancers.

Additionally, chemotherapy reduces pain and other problems caused by the bone marrow tumor and can cure the blood cancer completely, if treated at a proper time. Furthermore, the chemotherapy treatment can be used for all the age groups and for both the genders in the same manner. Due to this fact, chemotherapy is one of the most popular therapy among all the other therapies.

In chemotherapy, a combination of drugs is used to destroy as many leukemia cells as possible and bring blood counts to normal. Then, intensification chemotherapy is intended to destroy remaining leukemia cells that cannot be seen in the blood or bone marrow.

Thus, owing to the various advantages and applications offered by chemotherapy, there will be an increase in the demand chemotherapy, which in turn will drive the hematological cancer (blood cancer) therapy market growth in the forecast period from 2022 - 2027.

North America is expected to dominate the overall Hematological Cancer (Blood Cancer) Therapeutics:

Among all the regions, North America is expected to dominate the global hematological cancer (blood cancer) therapeutics in the year 2021 and is expected to do the same during the forecast period from 2022-2027.

Increasing research & developmental activities such as, therapy development for blood cancer and the rising prevalence of blood cancer due to gene mutations, smoking, radiation, viruses, cancer-causing chemicals (carcinogens), hormones, unhealthy lifestyle, and a lack of exercise will increase the demand for hematological cancer (blood cancer) therapy in North America, leading to a rise in the overall hematological cancer (blood cancer) therapy market growth.

For instance, according the American Cancer Society 2022, it was estimated that in 2022, 60,650 new cases of leukemia will be diagnosed in the US and 24,000 people will die from the disease.

Additionally, according to Leukemia & Lymphoma Society 2021, an estimated combined total of 186,400 people in the United States were diagnosed with leukemia, lymphoma or myeloma in 2021. As per the same source, approximately every 3 minutes, one person in the United States is diagnosed with leukemia, lymphoma or myeloma. The above source, also stated that nearly 1,519,907 people in the United States were living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPNs) in the year 2021.

Further, as per the Canadian Cancer Society 2021, the incidence of leukemia in Canada and in males was reported to be 3.4% and in women was nearly 2.4%. On the other hand, according to the Global Cancer Observatory 2021, the incidence of leukemia in the year 2020 was found to be 6,955. Thus, the above mentioned sources states that the prevalence of blood cancer is quite high in all of the regions of North America.

Thus, the increasing prevalence of blood cancer across the North America will increase the demand of hematological cancer (blood cancer) therapy, thereby propelling the overall market growth in the North America during the forecast period.

Hematological Cancer (Blood Cancer) Therapeutics Key Players:

Some of the key market players operating in the hematological cancer (blood cancer) therapeutics include Pfizer Inc., F. Hoffmann-LA Roche Ltd, Sanofi SA, Bristol-Myers Squibb Company, AbbVie Inc, Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Takeda Pharmaceutical Co. Ltd, Johnson & Johnson, Incyte Corporation, AstraZeneca PLC, Celldex Therapeutics Inc., Kite Pharma (Gilead Sciences), Atara Biotherapeutics, Celgene Corporation, Astellas, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC., and others.

Recent Developmental Activities in the Hematological Cancer (Blood Cancer) Therapeutics:

In June 2021, AbbVie acquired the TeneoOne and its key immunotherapeutic asset for treating blood cancer named TNB-383B.

In April 2021, U.S. Food and Drug Administration (FDA) had announced the approval of BCMA-targeted CAR T-Cell Therapy for the treatment of blood cancer.

Key Takeaways from the Hematological Cancer (Blood Cancer) Therapeutics Report Study

Market size analysis for current hematological cancer (blood cancer) therapeutics (2021), and market forecast for 5 years (2022-2027)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the hematological cancer (blood cancer) therapeutics

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years

Key companies dominating the global hematological cancer (blood cancer) therapeutics

Various opportunities are available for the other competitor in the hematological cancer (blood cancer) therapeutics space.

What are the top-performing segments in 2021? How these segments will perform in 2027.

Which are the top-performing regions and countries in the current hematological cancer (blood cancer) therapeutics scenario?

Which are the regions and countries where companies should have concentrated on opportunities for hematological cancer (blood cancer) therapeutics growth in the coming future?

Target Audience who can be benefited from this Hematological Cancer (Blood Cancer) Therapeutics Report Study

Hematological cancer (blood cancer) therapeutics providers

Research organizations and consulting companies

Hematological cancer (blood cancer) therapeutics -related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and traders dealing in hematological cancer (blood cancer) therapeutics

Various end-users who want to know more about the hematological cancer (blood cancer) therapeutics and the latest technological developments in the hematological cancer (blood cancer) therapeutics

Frequently Asked Questions for Hematological Cancer (Blood Cancer) Therapeutics:

1. What is Haematological Cancer (Blood Cancer) Therapeutics?

Haematological cancer or blood cancer therapeutics are the therapies and devices available in the market used for the treatment or management of the blood cancers.

2. What is the market for Global Haematological Cancer (Blood Cancer) Therapeutics?

The global hematological cancer or blood cancer therapeutic market was valued at USD 56.59 billion in 2021, growing at a CAGR of 10.14% during the forecast period from 2022 to 2027 to reach USD 100.80 billion by 2027.

3. What are the drivers for the Global Haematological Cancer (Blood Cancer) Therapeutics?

The hematological cancer (blood cancer) therapeutics is witnessing a positive market growth owing to the factors such as rising prevalence of blood cancers, increasing prevalence of lifestyle disorders, increasing research and development activities in arena of leukaemia and its treatment, and the rise in the regulatory approvals for hematological cancer (blood cancer) therapeutics.

4. Who are the key players operating in the Haematological Cancer (Blood Cancer) Therapeutics?

Some of the key market players operating in the Haematological Cancer (Blood Cancer) Therapeutics include Pfizer Inc., F. Hoffmann-LA Roche Ltd, Sanofi SA, Bristol-Myers Squibb Company, AbbVie Inc, Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Takeda Pharmaceutical Co. Ltd, Johnson & Johnson, Incyte Corporation, AstraZeneca PLC, Celldex Therapeutics Inc., Kite Pharma (Gilead Sciences), Atara Biotherapeutics, Celgene Corporation, Astellas, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC., and others.

5. Which region has the highest share in Haematological Cancer (Blood Cancer) Therapeutics?

North America is expected to dominate the global Haematological Cancer (Blood Cancer) Therapeutics. Factors contributing to the growth are the increasing incidence of blood cancers, and the rise in the regulatory approvals for hematological cancer (blood cancer) therapies, which are contributing to the growth of the hematological cancer (blood cancer) therapeutics in the North American region."


Please Note: It will take 7-10 business days to complete the report upon order confirmation.